BUSINESS● LOW1h ago · Sep 4, 2026, 9:16 PM
Matinas BioPharma gets 2027 window to restore NYSE American listing compliance
Seeking Alpha Tech · north america
Matinas BioPharma has been granted until 2027 to regain compliance for its NYSE American listing. This reports an important regulatory development for the company's stock market status.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS46m agoBloom Energy surges on inclusion to S&P 500; Illumina, Everpure also addedSeeking Alpha TechBUSINESS1h agoLed by Quintana Roo, Mexico’s tourism GDP ranks fourth globally, according to the World Travel & Tourism CouncilMexico News DailyBUSINESS1h agoTalk is growing of a Tesla-SpaceX merger. Will geopolitics throw a spanner in the works?South China Morning PostBUSINESS1h agoStardust Solar Energy launches $641,000 private placementSeeking Alpha Tech